Executive Summary

NeuroAI is emerging as one of the most important technology frontiers at the convergence of neuroscience and artificial intelligence. Driven by rapid advances in AI, digital biomarkers, brain-computer interfaces (BCIs), neurotechnology, and computational neuroscience, the NeuroAI ecosystem is expanding beyond traditional healthcare into education, consumer technology, robotics, and human performance.

Unlike conventional AI, which primarily processes language, images, and structured data, NeuroAI focuses on understanding, modeling, and enhancing human brain function.

Today, the global NeuroAI ecosystem encompasses companies developing:

• Brain-inspired AI architectures
• Brain-computer interfaces (BCIs)
• Brain data, intelligence and digital biomarkers
• Consumer neurotechnology
• Digital neurotherapeutics
• Developmental NeuroAI

This report provides a high-level overview of representative organizations shaping the NeuroAI ecosystem in 2026.

The NeuroAI Ecosystem

NeuroAI can be broadly divided into six technology domains.

Sector Mapping & Representative Companies

1. Brain-Inspired AI

Building the next generation of AI inspired by biological intelligence.

2. Brain–Computer Interfaces (BCI)

Connecting brains and machines through AI-powered neural decoding.

3. Brain Data Intelligence & Digital Biomarkers

Transforming brain, cognitive, and behavioral data into actionable intelligence.

4. Consumer Neurotechnology

Making brain sensing accessible in everyday life.

5. Digital Neurotherapeutics

Delivering evidence-based brain interventions through software and AI.

6. Developmental NeuroAI

Applying AI to understand and support brain development across the lifespan.

Landscape Summary & Key Insights

Domain Distribution

Key Industry Observations

1. Convergence of Neurotechnology and Multimodal AI

NeuroAI is rapidly expanding beyond isolated laboratory settings. As multimodal AI models progress, neural signals (EEG, fNIRS, sEEG) are being combined with speech, eye-tracking, and sensorimotor behavioral data to form unified brain-state models.

2. Shift toward Non-Invasive Digital Biomarkers

While invasive BCI companies (e.g., Neuralink, Paradromics) dominate high-bandwidth therapeutic headlines, non-invasive digital biomarkers (speech, eye-tracking, smartphone interactions) are driving the fastest scalability in pharma trials and early disease detection.

3. Developmental NeuroAI as the Next Frontier

Early screening for neurodevelopmental disorders (such as Autism Spectrum Disorder and ADHD) traditionally suffers from multi-year clinical diagnostic delays. Emerging NeuroAI platforms leveraging mobile devices offer scalable, objective tools that bridge pediatric care, education, and family-led early intervention.